VivoSeq
Oncology

Chronic Myelomonocytic Leukemia

74

Pipeline Programs↗

24

Active Trials↗

41

Companies Involved↗

Chronic Myelomonocytic Leukemia is a moderately active landscape with 74 programs across 41 companies. The most active players are EMD Serono, Boehringer Ingelheim, Amgen. 1 therapy is approved with 6 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

67/100

Pipeline Velocity

19/100

Mech. Concentration

7/100

Completion Rate

72/100

Attrition Rate

17/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

EMD Serono logo

EMD Serono

2 programs

Phase 1Boehringer Ingelheim logo

Boehringer Ingelheim

1 program

Phase 1Amgen logo

Amgen

1 program

Phase 1E

Eastern Cooperative Oncology Group

1 program

Phase 1C

Cardiff Oncology

1 program

Phase 1Gilead logo

Gilead

1 program

Phase 1

Pipeline

Programs by Phase

Analysis

Modality Breakdown

84%

Small molecule

62 of 74 classified programs — the dominant modality here.

16%ALL OTHERSMonoclonal antibody79%Protein / enzyme45%Cell therapy11%

Small molecule leads; the ring shows all 74 classified programs, each share of the total. Modality classified for 100% of 78 pipeline programs.

Analysis

Trial Status

65

clinical trials

Completed28 · 43%
Recruiting13 · 20%
Active, not recruiting9 · 14%
Terminated8 · 12%
Withdrawn3 · 5%
Not yet recruiting2 · 3%
Other2 · 3%

Clinical Trials

Trial Activity

65 trials

A Phase II, Open-Label, Study of Subcutaneous Canakinumab, an Anti-IL-1β Human Monoclonal Antibody, for Patients With Low or Int-1 Risk IPSS/IPSS-R Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia
Recruiting·MM.D. Anderson Cancer Center·Phase 2·NCT04239157·76 enrolled
A Phase II Study of Cladribine and Low Dose Cytarabine in Combination With Venetoclax, Alternating With Azacitidine and Venetoclax, in Patients With Higher-risk Myeloproliferative Chronic Myelomonocytic Leukemia or Higher-risk Myelodysplastic Syndromes With Excess Blasts
Recruiting·MM.D. Anderson Cancer Center·Phase 2·NCT05365035·60 enrolled
A Phase 2 Study Evaluating Olutasidenib in Combination With Hypomethylating Agents in Patients With IDH1-mutated Higher-risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Advanced Myeloproliferative Neoplasm
Recruiting·MM.D. Anderson Cancer Center·Phase 2·NCT06597734·45 enrolled
Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia
Recruiting·MMayo Clinic·Phase 2·NCT03418038·80 enrolled
CLAG-M or FLAG-Ida Chemotherapy and Reduced-Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelomonocytic Leukemia
Recruiting·FFred Hutchinson Cancer Center·Phase 1·NCT04375631·120 enrolled
IMM01+Azacitidine VS Placebo +Azacitidine in Patients With Newly Diagnosed Chronic Myelomonocytic Leukemia (CMML1-2)
Recruiting·IImmuneOnco Biopharmaceuticals (Shanghai) Inc.·Phase 3·NCT06647862·170 enrolled
CPX-351 in Treating Patients With Relapsed or Refractory High Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia
Recruiting·MM.D. Anderson Cancer Center·Phase 1·NCT03896269·38 enrolled
Pacritinib vs. Hydroxyurea in Advanced Proliferative Chronic Myelomonocytic Leukemia
Recruiting·TTheradex·Phase 2·NCT07033598·66 enrolled
Azacitidine, Venetoclax, and Gilteritinib in Treating Patients With Recurrent/Refractory FLT3-Mutated Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, or High-Risk Myelodysplastic Syndrome/Myeloproliferative Neoplasm
Recruiting·MM.D. Anderson Cancer Center·Phase 1/2·NCT04140487·97 enrolled
Phase I/II Clinical Trial of Axatilimab, a CSF1R Monoclonal Antibody, in Combination With Ruxolitinib as Therapy for Patients With Myelofibrosis (MF) and Chronic Myelomonocytic Leukemia (CMML)
Recruiting·MM.D. Anderson Cancer Center·Phase 1/2·NCT07128381·66 enrolled
Seclidemstat and Azacitidine for the Treatment of Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia
Recruiting·MM.D. Anderson Cancer Center·Phase 1/2·NCT04734990·44 enrolled
Axatilimab With or Without Azacitidine for the Treatment of Patients With Advanced Phase Myeloproliferative Neoplasms, Myeloproliferative Neoplasm/Myelodysplastic Syndrome Overlap or High Risk Chronic Myelomonocytic Leukemia
Recruiting·—·Phase 1/2·NCT06523556·52 enrolled
CD4CAR T Cell Therapy for CMML
Recruiting·—·Phase 1·NCT06071624·30 enrolled
Azacitidine Combined With Venetoclax in Patients With Higher-risk Chronic Myelomonocytic Leukemia (AVENHIR)
Active, not recruiting·GGroupe Francophone des Myelodysplasies·Phase 2·NCT05768711·44 enrolled
A Study Comparing Treatment Preference Between Oral Decitabine/Cedazuridine and Azacitidine in Myelodysplastic Syndrome, Low-Blast Acute Myeloid Leukemia, or Chronic Myelomonocytic Leukemia
Active, not recruiting·Otsuka logoOtsuka·Phase 3·NCT05883956·13 enrolled
Page 1 of 5

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)